Milestone Scientific (MLSS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Annual Meeting scheduled for July 27, 2026, to be held virtually, with shareholders able to vote and submit questions online.
Key proposals include director elections, amendments to increase authorized shares and equity plan shares, say-on-pay, and auditor ratification.
Proxy materials and annual report are available online, with notice and access procedures to reduce costs and environmental impact.
Record date for voting is May 28, 2026, with 88,449,412 shares outstanding.
Voting matters and shareholder proposals
Proposals: elect five directors, increase authorized common stock to 135,000,000, amend equity plan to 28,750,000 shares, advisory say-on-pay, ratify Grassi & Co. as auditors, and other business.
Only auditor ratification is considered a routine matter for broker voting; other proposals require direct shareholder instruction.
Majority of votes cast required for approval of all proposals except director election, which is by plurality.
Board recommends voting in favor of all proposals.
Board of directors and corporate governance
Board consists of six members, four independent; five nominees for election, with one current director not seeking re-election.
Leadership structure separates Chairman and CEO roles for effective governance.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, each with written charters.
Independence confirmed for key directors; stockholder communications process established.
Code of Ethics and Clawback Policy in place, with compliance to SEC and NYSE standards.
Latest events from Milestone Scientific
- Virtual meeting to vote on directors, share increases, equity plan, pay, and auditor ratification.MLSS
Proxy filing10 Jun 2026 - Virtual meeting to vote on directors, share increases, equity plan, pay, and auditor ratification.MLSS
Proxy filing5 Jun 2026 - Resale registration for 15.9M shares after $2.15M private placement; faces funding and compliance risks.MLSS
Registration filing2 Jun 2026 - Q1 2026 saw stable revenue, sharply reduced losses, and improved liquidity amid ongoing risks.MLSS
Q1 202615 May 2026 - 2026 guidance projects double-digit growth and major CompuFlo gains, targeting break even by 2027.MLSS
Q4 20251 Apr 2026 - Q2 net income turned positive on a $2M NOL sale, with strong e-commerce and margin gains.MLSS
Q2 20241 Feb 2026 - Expanding into the $2B epidural market with patented tech, strong margins, and new Medicare coverage.MLSS
Lytham Partners Fall 2024 Investor Conference20 Jan 2026 - Commercialization accelerates with Medicare pricing, new partnerships, and strong clinical impact.MLSS
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 revenue up 22% with strong dental growth, regulatory wins, and improved net loss.MLSS
Q3 202413 Jan 2026